Innate Immune Checkpoints & Activation Pre-Conference Focus Day

Tuesday 9th May 2023

8:30 am
Registration & Welcome Coffee

8:55 am Chair’s Opening Remarks

Enhancing Checkpoint Inhibition in Combination Approaches With STING Agonists

9:00 am Immune Activation by A Dual Acting STING Agonist: Potential for Monotherapy Activity Enhanced by Immune Checkpoint Inhibitor Combination


  • Discover how intratumoral injection of a potentiated STING agonist activates the innate and adaptive immune system
  • Explore how adaptive immunity is enhanced by anti-PD-L1 antibodies
  • Learn about the abscopal anti-tumor effects that can be observed in potentiated STING activity

9:30 am Panel Discussion: Overcoming Adaptive & Primary Resistance That Limits the Long-Term Utility of Immune Checkpoint Inhibitors: Moving on From Monotherapies


  • From CTLA-4 to PD-(L)1: how immune checkpoint inhibition shifted the way we approach treating many cancers
  • Understanding the limitations of checkpoint inhibition and why the response rate to PD-1 inhibition can be as low as 10%
  • Considering combination approaches to overcome resistance and see a durable response

10:00 am Combination of Anti-VEGFR2 & STING Agonist Results in Complete Triple Negative Breast Cancer Curation


  • Engineering non-viral nanoparticle-based delivery system for STING agonist delivery in combination with anti-VEGFR2 for the treatment of triple negative breast cancer (TNBC)
  • Elucidating the role of administration route (i.v., i.t., local and sustained) of anti-VEGFR2 and STING agonist on TNBC therapeutic efficacy in orthotopic, syngeneic TNBC mouse models
  • Characterizing the molecular and cellular responses to the therapy using immunophenotyping

10:30 am Panel Discussion: Kickstarting Both Innate & Adaptive Immune Response Through IL2 Immunotherapy in Conjunction With STING Stimulation


  • Minimizing cytokine exposure while maximizing the effectiveness of IL2 therapy
  • Uncovering promising data – looking at how the cytokine factory approach has seen dramatic improvement in rodent models without recurrence
  • Analyzing rodent blood chemistry ranges to indicate efficacy and safety

11:30 am
Lunch Break

Understanding How Checkpoint Inhibitor Combinations Translate Into Treatments for Specific Indications

12:30 pm M4SF1: An Attractive Vascular & Tumor Cell Target for Solid Tumor Therapy


  • TM4SF1 is a novel and attractive target for solid tumor therapy
  • TM4SF1 offers a unique payload delivery mechanism for antibody-drug-conjugates (ADCs)
  • TM4SF1 ADCs may be a favorable method for delivering STING agonists in solid tumors

1:00 pm CD24: A New Approach to Treating B-Cell Leukaemia & Lymphoma


  • Understanding the mechanism of action in which direct binding of anti-CD24 mAb results in clustering of CD24 to stimulate apoptosis, recruit NK cells and induce ADCC and complement-mediated cytotoxicity and employ phagocytes to the site of the tumor
  • Combining CD24 with NK cell targeting to enhance ADCC in liver cancers

1:30 pm End of Pre-Conference Focus Day